Aduro Biotech, Inc. (Nasdaq: ADRO) has received notice from the U.S. Food and Drug Administration (FDA) that trials with investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE